China Offers Alternative Gateway for Experimental Drugs  

Oleh:

Hepeng Jia ; Kling, Jim

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Nature Biotechnology: The Science and Business of Biotechnology vol. 24 no. 2 (Feb. 2006), page 117-118.
Topik: drugs; gateway; experimental drugs

Ketersediaan

Perpustakaan Pusat (Semanggi) Nomor Panggil: NN9.4 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Several experimental biologic drugs pioneerred by western biotech companies that failed to reach the US or european markets have recently been approved in china. Some argue that china could prove a useful testing ground from which to launch experimental therapies into the west. Others argue that it will take more than a flexible regulatory regime to kickstart chinese biotech startup activity or convince foreign biotech companies to carry out testing in china. Last november, the beijing based chinese state food and drug administration (SFDA) approved H101, the first oncolytic virus to be commmercialized...

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali